Don't Switch Most Stent Patients From Clopidogrel to Another Antiplatelet Med

January 2016

We're getting questions about the efficacy of long-term clopidogrel (Plavix, etc)...due to a new report from FDA.

This started because of a study suggesting that coronary stent patients taking clopidogrel plus aspirin have a higher risk of death.

The good news is that this risk doesn't pan out when data from several trials are combined.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote